Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey

A Real-World Experience of Clinical, Biochemical and Genetic Assessment of Patients with Homozygous Familial Hypercholesterolemia

(2020) Maria Donata Di Taranto et al.   Journal of Clinical Medicine

Homozygous familial hypercholesterolemia

(2020) Archna Bajaj et al.   CURRENT OPINION IN LIPIDOLOGY

Cholesterol-Lowering Agents

(2019) Robert S. Rosenson et al.   CIRCULATION RESEARCH

A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolaemia: the Sino-Roman Study

(2019) Claudia Stefanutti et al.   Journal of Clinical Lipidology

Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989–2017

(2019) Alison Pottle et al.   ATHEROSCLEROSIS

Autosomal Recessive Hypercholesterolemia

(2018) Laura D’Erasmo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort

(2018) Sophie Beliard et al.   ATHEROSCLEROSIS

Familial hypercholesterolemia treatments: Guidelines and new therapies

(2018) Frederick J. Raal et al.   ATHEROSCLEROSIS

Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol

(2017) Gilbert R Thompson et al.   EUROPEAN HEART JOURNAL

Lomitapide for the treatment of hypercholesterolemia

(2017) Amanda J. Berberich et al.   EXPERT OPINION ON PHARMACOTHERAPY

Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia

(2017) Antonio Gallo et al.   Journal of Clinical Lipidology

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

(2017) Frederick J Raal et al.   Lancet Diabetes & Endocrinology

The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients

(2016) Sophie Béliard et al.   Journal of Clinical Lipidology

Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry

(2016) Rodrigo Alonso et al.   Journal of Clinical Lipidology

Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia

(2016) P. Barton Duell et al.   Journal of Clinical Lipidology

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

(2014) M. Cuchel et al.   EUROPEAN HEART JOURNAL

Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy

(2011) Frederick J. Raal et al.   CIRCULATION

Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe

(2010) Gilbert R Thompson et al.   CURRENT OPINION IN LIPIDOLOGY

Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial Hypercholesterolemia

(2008) Daniel M. Kolansky et al.   AMERICAN JOURNAL OF CARDIOLOGY